Alteplase Articles
Reteplase Backed By FDA Panel
13 May 1996
Revenues Up But Profits Down At Genentech
22 April 1996
Supplemental NDA filed for Activase
25 March 1996
Citicoline Improves Outcomes In Stroke
26 February 1996
Trial of Genentech's Activase expanded
29 January 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Activase Shows Promise In Stroke; Filing Set For 1996?
8 January 1996
Hoffmann-La Roche acquires rights to Genentech products
18 December 1995
Genentech And Roche Strengthen Relationship
6 November 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
B-MS To Develop GI's New Thrombolytic
30 October 1995
Reteplase Holds Promise For Acute MI Patients
14 August 1995
Genentech Takes Special Charge In 2nd Qtr
24 July 1995
The Biopharmaceutical Industry To Come
17 July 1995
Good Performance Forecast For Euro Drugmakers
26 June 1995
Boehringer Ingelheim In Talks With US Co
5 June 1995
Pharmacoeconomic Data From GUSTO Supports tPA
5 June 1995
Weaker US Dollar And Volume Growth Lift 1st Qtr
24 April 1995
Introducing Biopharma Drugs Into Europe
17 April 1995
NEW YORK STOCK COMMENT
10 April 1995
Accelerated Activase Regimen Approved
10 April 1995
GUSTO III Study To Start In Summer
27 March 1995
Questions Raised Over Genentech's Marketing
23 January 1995
Genentech Files IND For tPA Follow-up
12 December 1994
Genentech Responds To GUSTO Probe Claim
21 November 1994
FDA Broadens Genentech Probe
14 November 1994
US 3rd Quarter Shows Growth Despite Pressures
24 October 1994
Genentech Presentation Pleases Analysts
17 October 1994
Genentech's TNK-t-PA Data
25 July 1994
US Biotech Cos Top Earnings At 1st Half
25 July 1994
FAVORABLE RULING FOR GI OVER NPA
4 July 1994
US ANTITHROMBOSIS MARKET FORECASTS
27 June 1994
C-22 AND C-91 HAVE SURPASSED PROMISES SAYS PMAC
27 June 1994
FDA PANEL BACKS ACCELERATED T-PA
20 June 1994
UNCLOGGING THE ISSUES IN THROMBOLYSIS
13 June 1994
PROFITS MORE THAN DOUBLE AT GENENTECH
25 April 1994
GENENTECH 1st QTR MEETS FORECASTS
11 April 1994
"EXCELLENT"RESULTS FROM GENENTECH
24 January 1994
CANADIAN FIRMS GIVING UP PATENTS
17 January 1994
RESEARCH AND INVESTMENT IN CARDIOLOGY
20 December 1993
NEW DATA ON ACTIVASE FROM GUSTO TRIAL
29 November 1993
RESULTS FROM PHASE II TIMI-5 STUDY
22 November 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
US BIOTECH PRODUCTS IN R&D (Cont'd from last issue)
4 October 1993
NEW TRIAL RESULTS REPORTED AT ECCO
20 September 1993
THROMBOLYSIS DEBATE RESTARTS WITH GUSTO
13 September 1993
GENENTECH HALTS STILE STUDY
6 September 1993
PROFITS SOAR FOR GENENTECH IN 2ND QTR
19 July 1993
GENENTECH CUTS CANADIAN T-PA PRICE
14 June 1993
NEW YORK STOCK COMMENT
17 May 1993
T-PA BACKED BY GUSTO STUDY RESULTS
10 May 1993
ROCHE FORESEES GOOD OUTLOOK FOR 1993
3 May 1993
US 1st QTRs IN LINE WITH EARLIER WARNINGS
26 April 1993
PROFITS FALL AT KYOWA HAKKO
22 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
REVENUES RISE AT GENENTECH
25 January 1993
CLINTON VICTORY GOOD FOR SOME PHARMA COS
9 November 1992
NORTH AMERICAN NEWS IN BRIEF
7 September 1992
TOYOBO CALLS HALT TO t-PA SALES
6 July 1992
WORLD PRODUCT NEWS IN BRIEF
15 June 1992
PROFITS DIVE AT MITSUBISHI KASEI
15 June 1992
GENENTECH'S EXPANDING PRODUCT PORTFOLIO
11 May 1992
IMPROVEMENTS IN 1ST QTR FOR US FIRMS
20 April 1992
GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO
6 April 1992
GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO
6 April 1992
EFPIA CHALLENGES EC DRAFT ON DRUG PRICING
16 March 1992
1991 A YEAR OF STRONG GROWTH IN THE USA
27 January 1992
GENENTECH EXPECTS FLAT YEAR IN 1992
13 January 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
